David Ferreira Shares 3 Pillars of Patient Blood Management
David Ferreira, Director of the Immuno-hemotherapy Service at ULSGE at Gaia and Espinho Local Health Unit, shared on LinkedIn:
”Patient Blood Management (PBM) is a structured clinical approach that seeks to optimize the patient’s hematological status, reduce avoidable blood loss, and ensure that transfusions are only used when truly necessary.
Its strength comes from these three pillars:
- Optimize erythropoiesis — Diagnose and treat anemia before invasive procedures or in chronic patients;
- Minimize blood loss — Surgical, anesthetic, and laboratory strategies with less waste;
- Improve tolerance to anemia — Make individualized transfusion decisions, avoiding unnecessary transfusions.
The benefits are clear:
- Fewer avoidable transfusions
- Fewer complications
- Better recovery
- Responsible use of a scarce resource
At the Gaia and Espinho Local Health Unit, even in a context of great pressure on the Immuno-Hemotherapy Service, we hold regular PBM consultations every week, reinforcing our commitment to our patients.
This work is only possible thanks to the dedication of our medical and nursing teams in our small Day Hospital, who ensure a continuous and technically demanding response.
PBM is not just a technique—it is a culture of safety, quality, and respect for patients and donors.
And it lives on at ULSGE.
We continue, with rigor and resilience.”
Stay updated with Hemostasis Today.
-
Nov 5, 2025, 10:45David Ferreira Shares 3 Pillars of Patient Blood Management
-
Nov 5, 2025, 10:43The November Issue of The Lancet Haematology is Out!
-
Nov 5, 2025, 10:10Hossam El Benawi on Impact of Timing of Atrial Fibrillation Ablation
-
Nov 5, 2025, 08:30Claire Auditeau: Thrilled to Share a Major Milestone From My PhD Journey!
-
Nov 5, 2025, 06:51Petros Gatsios Explains Why Europe Must Become Self-Sufficient in Maintaining Its Plasma Supply
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 4, 2025, 06:37AI Meets Cardiology Guidelines․ Our JACC Study Is Live
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!